Piper Sandler Raises ABBV Price Target to $303 as Stock Nears 52-Week High

By TrendSpider Editor

The forward setup for AbbVie looks constructive heading into the back half of 2026. The stock's proximity to its 52-week high of $267.47 makes a clean breakout the key technical event to watch. A decisive move above that level, supported by analyst confidence reflected in the Piper Sandler target ra

Piper Sandler Raises ABBV Price Target to $303 as Stock Nears 52-Week High

Key Drivers of the ABBV Stock Move

• Main Catalyst: Piper Sandler's David Amsellem confirmed a buy rating on AbbVie and raised the firm's price target by $5, moving it from $298 to $303. The action reflects a maintained high-conviction stance rather than a new initiation, suggesting the analyst sees sustained fundamental strength ahead.
• Bull Case: The revised price target of $303 implies additional upside from the current price of $266.64. The confirmation follows a session gain of 1.81%, and the stock is trading near the top of its 52-week range with the high end at $267.47, suggesting technical momentum is aligned with the positive analyst sentiment.
• Bear Case: With ABBV trading at $266.64 and the 52-week high sitting at $267.47, the stock is operating in technically extended territory. A confirmation rather than a fresh upgrade may carry limited incremental weight for institutional investors already familiar with the bull case, and any failure to break above the 52-week high could trigger near-term selling pressure.

The forward setup for AbbVie looks constructive heading into the back half of 2026. The stock's proximity to its 52-week high of $267.47 makes a clean breakout the key technical event to watch. A decisive move above that level, supported by analyst confidence reflected in the Piper Sandler target raise to $303, could attract momentum-oriented buyers. At the same time, the stock has already made a substantial run from the 52-week low of $191, which means the risk-reward calculation is becoming more nuanced. Investors will be watching for any incremental pipeline or commercial updates that could give the market a fresh fundamental catalyst to justify new highs.

ABBV Analyst Ratings and Price Targets

Piper Sandler analyst David Amsellem confirmed a buy rating on AbbVie on August 21, 2026, raising the firm's price target to $303 from a prior target of $298. The average price target across analysts currently stands at $303, consistent with the updated Piper Sandler figure. No upgrades or downgrades were recorded in this action, reflecting a reaffirmation of an existing positive stance rather than a directional rating change.

ABBV Seasonality

Late August has historically been a mixed period for large-cap pharmaceutical stocks as summer trading volumes thin out and investors begin to position ahead of fall medical conferences, which can serve as meaningful catalysts for pipeline-driven names like AbbVie. A positive analyst reaffirmation at this point in the calendar can carry added weight if it helps set the narrative heading into a traditionally more active fall trading season.

ABBV Relative Performance

AbbVie's 1.81% gain on Friday outpaces typical single-session moves for large-cap healthcare peers, and the stock's position near its 52-week high of $267.47 contrasts favorably with the broader pharmaceutical sector, which has faced uneven performance in 2026. Trading at $266.64, AbbVie sits dramatically above its 52-week low of $191, reflecting a sustained period of outperformance that has drawn continued analyst support.